CorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical Operations...
March 11 2021 - 8:30AM
CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused
on developing and commercializing therapeutic products for the
prevention and treatment of infectious and inflammatory disease,
today announced that it has entered into a new three-year
Employment Agreement with Liz Masson-Hurlburt, currently Executive
Vice President and Head of Clinical Operations. The new agreement
terminates in March 2024, and may be extended annually thereafter
upon mutual agreement.
“I am delighted that Liz has agreed to continue in her current
role at this critical time as we are continuing to work toward a
potential FDA approval of DefenCath and in parallel laying the
groundwork for programs to advance DefenCath into other patient
segments beyond hemodialysis,” said Khoso Baluch, Chief Executive
Officer of CorMedix. “She has been instrumental in bringing the
LOCK-IT 100 clinical study to a successful completion and assisting
in the responses to the FDA during the review of the New Drug
Application. Her expertise in clinical operations will be important
as we develop potential indications for DefenCath in oncology and
total parenteral nutrition.”
Ms. Masson-Hurlburt joined CorMedix in March 2018 and was
instrumental in bringing the LOCK-IT-100 clinical study to a
successful completion. Prior to CorMedix, she held several
progressive management roles in clinical operations, most recently
at Gemphire Therapeutics, as Vice President, Clinical Operations.
Responsible for strategic and operational development activities,
Liz has a passion for growing and developing highly engaged teams
and assuring the highest standards for program execution. Liz
received her B.A. in Leadership and Organizational Management from
Bay Path College.
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on
developing and commercializing therapeutic products for the
prevention and treatment of infectious and inflammatory diseases.
The Company is focused on developing its lead product DefenCath™, a
novel, antibacterial and antifungal solution designed to prevent
costly and life-threatening bloodstream infections associated with
the use of central venous catheters in patients undergoing chronic
hemodialysis. DefenCath has been designated by FDA as Fast Track
and as a Qualified Infectious Disease Product, which provides an
additional five years of marketing exclusivity, which will be added
to the five years granted to a New Chemical Entity upon approval of
a New Drug Application (NDA). The NDA was filed with FDA and the
Company has been informed in a Complete Response Letter (CRL) that
approval requires resolution of deficiencies at the third-party
manufacturing facility. CorMedix also intends to develop DefenCath
as a catheter lock solution for use in oncology and total
parenteral nutrition patients. It is leveraging its taurolidine
technology to develop a pipeline of antimicrobial medical devices,
with programs in surgical sutures and meshes, and topical
hydrogels. The Company is also working with top-tier researchers to
develop taurolidine-based therapies for rare pediatric cancers.
Neutrolin™ is CE Marked and marketed in Europe and other
territories as a medical device. For more information, visit:
www.cormedix.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks and uncertainties. All
statements, other than statements of historical facts, regarding
management’s expectations, beliefs, goals, plans or CorMedix’s
prospects, future financial position, financing plans, future
revenues and projected costs should be considered forward-looking.
Readers are cautioned that actual results may differ materially
from projections or estimates due to a variety of important
factors, including: the results of our discussions with the FDA
regarding the DefenCath development path; the resources needed to
secure approval of the new drug application for DefenCath from the
FDA, including manufacturing at a third-party facility; the risks
and uncertainties associated with CorMedix’s ability to manage its
limited cash resources and the impact on current, planned or future
research, including the continued development of
DefenCath/Neutrolin and research for additional uses for
taurolidine; obtaining additional financing to support CorMedix’s
research and development and clinical activities and operations;
preclinical results are not indicative of success in clinical
trials and might not be replicated in any subsequent studies or
trials; and the ability to retain and hire necessary personnel to
staff our operations appropriately. At this time, we are unable to
assess whether, and to what extent, the uncertainty surrounding the
Coronavirus pandemic may impact our business and operations. These
and other risks are described in greater detail in CorMedix’s
filings with the SEC, copies of which are available free of charge
at the SEC’s website at www.sec.gov or upon request from CorMedix.
CorMedix may not actually achieve the goals or plans described in
its forward-looking statements, and investors should not place
undue reliance on these statements. CorMedix assumes no obligation
and does not intend to update these forward-looking statements,
except as required by law.
Investor Contact:
Dan FerryManaging DirectorLifeSci Advisors617-430-7576
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024